Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962109 | 0.82 | TARBP2 (0.35) | FBP1TARBP2ALDH1A1MAPTCTSV | |
| SCHEMBL16417693 | 0.78 | MLYCD (0.36) | FBP1TARBP2ALDH1A1 | |
| SCHEMBL10767490 | 0.78 | GSK3B (0.32) | GSK3BTARBP2BACE1 | |
| SCHEMBL8880363 | 0.77 | GSK3B (0.35) | GSK3BFBP1ALDH1A1 | |
| SCHEMBL8613414 | 0.74 | IKBKB (0.38) | FBP1TARBP2ALDH1A1BACE1 | |
| SCHEMBL287238 | 0.74 | ALDH1A1 (0.33) | FBP1TARBP2ALDH1A1MEN1MAPT | |
| SCHEMBL3093844 | 0.73 | TARBP2 (0.60) | TARBP2ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL19119222 | 0.72 | PDE4B (0.33) | FBP1TARBP2ALDH1A1MEN1MAPT | |
| SCHEMBL3742227 | 0.72 | POLB (0.44) | FBP1ALDH1A1BACE1 | |
| SCHEMBL539776 | 0.72 | FBP1 (0.32) | FBP1TARBP2ALDH1A1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190016707-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION | 2019-01-17 | — | — | US | disclosed |
| EP-3325471-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | Genzyme Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015267-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2017-01-26 | — | — | WO | disclosed |
| US-5604225-A | DIETETICS; OBESITY | DR. KARL THOMAE GMBH (DE) | 1997-02-18 | — | — | US | disclosed |
| US-5457205-A | Substituted thiazoles useful for treatment of diabetes | DR. KARL THOMAE GMBH (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5219852-A | Hypoglycemic agents, treatment of diabetes and obesity | DR. KARL THOMAE GMBH (DE) | 1993-06-15 | — | — | US | disclosed |
| EP-0239815-B1 | SUBSTITUTED THIAZOLES AND OXAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1991-07-24 | — | — | EP | disclosed |
| US-4886814-A | LOWER BLOOD SUGAR | DR. KARL THOMAS GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0239815-A1 | Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885FBP1 419/4885TARBP2 2484/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885FBP1 419/4885TARBP2 2484/4885 |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885FBP1 419/4885TARBP2 2484/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3153/4885FBP1 405/4885TARBP2 1884/4885 |
| US-20190016707-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885FBP1 419/4885TARBP2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.